US2017276683A1PendingUtilityA1

Elisa for vegf

59
Assignee: GENENTECH INCPriority: Oct 4, 2006Filed: Mar 13, 2017Published: Sep 28, 2017
Est. expiryOct 4, 2026(~0.2 yrs left)· nominal 20-yr term from priority
Inventors:Yu-Ju G. MengKyu H. HongJohnny Gutierrez
G01N 33/57595C07K 16/22G01N 2333/475G01N 33/74G01N 33/57496
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . An antibody that does not bind VEGF 110 and which binds to the same epitope as the monoclonal antibody produced by the hybridoma cell line PTA-7737. 
     
     
         2 . The monoclonal antibody of  claim 1  which is conjugated to a detectable label.

Join the waitlist — get patent alerts

Track US2017276683A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.